Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.

ABSTRACT: Heart failure with preserved ejection fraction (HFpEF) is closely associated with metabolic derangement. Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) exert anti-HFpEF effects, but the underlying mechanisms remain unclear. In this study, we explored the anti-HFpEF effects of empagliflozin and liraglutide and the underlying molecular mechanisms in a mouse model of HFpEF. This model was established by high-fat diet (HFD) feeding plus N^ω-nitro-L-arginine methyl ester (L-NAME) treatment. The mice were treated with empagliflozin (20 mg·kg^-1·d^-1, i.g.) or liraglutide (0.3 mg·kg^-1·d^-1, i.p.) or their combination for 4 weeks. At the end of the experimental protocol, cardiac function

SUBMITTER: Ni XY 

PROVIDER: S-EPMC11272793 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature